Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
In this nationwide, population and registry-based study there was no overall survival benefit observed five years after the introduction of adjuvant treatment for patients with stage III melanoma. These findings encourage a careful assessment of the current recommendation on adjuvant treatment.
Authors
- Gustav Ullenhag (ORCID: https://orcid.org/0000-0003-4949-3267)
- Rasmus Mikiver (ORCID: https://orcid.org/0000-0002-0291-2279)
- Karolin Isaksson (ORCID: https://orcid.org/0000-0003-3690-5680)
- Hildur Helgadóttir (ORCID: https://orcid.org/0000-0002-0735-4771)
- Lars Ny (ORCID: https://orcid.org/0000-0003-3864-5958)
- Roger Olofsson Bagge
Institutions
- Linköping University (SE)
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- Regional Cancer Center (US)
- Skåne University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1016/j.ejca.2025.116201
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancerfonden